Patent classifications
A61P43/00
HETEROCYCLIC COMPOUND
- Yuhei MIYANOHANA ,
- Yuichi KAJITA ,
- Tatsuki KOIKE ,
- Yasutaka HOASHI ,
- Yasushi Hattori ,
- Norihito Tokunaga ,
- Tsuneo ODA ,
- Tohru Miyazaki ,
- Dilhumar UYGHUR ,
- Yoshiteru ITO ,
- Kohei TAKEUCHI ,
- Keisuke IMAMURA ,
- Takahiro SUGIMOTO ,
- Koichiro FUKUDA ,
- Yasuhisa KOHARA ,
- Rei OKAMOTO ,
- Taiichi OHRA ,
- Naoki MIYAMOTO ,
- Jun CHIBA ,
- Yoshito Terao ,
- Masanori KAWASAKI
The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):
##STR00001## wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
COMPOSITION
There is provided a composition that comprises a propionic acid bacterium or a composition that comprises an oligosaccharide. The composition that comprises a propionic acid bacterium or the composition that comprises an oligosaccharide can suppress an increase of body weight of a subject by having the subject ingest the composition.
SOLID COMPOSITION CONTAINING AMORPHOUS, POORLY WATER-SOLUBLE MATERIAL, AND METHOD FOR PRODUCING SAME
The present invention provides a solid composition containing an amorphous poorly water-soluble material, and a method for producing the same. The solid composition of the present invention is a solid composition containing an amorphous poorly water-soluble material (1a), hydroxypropylmethyl cellulose (2), and one or more types of water-soluble polysaccharides (3) other than hydroxypropylmethyl cellulose, and is characterized in that an XRD analysis value of the solid composition is 4.0% or less.
USE OF 5-METHYLTETRAHYDROFOLATE
Use of 5-methyltetrahydrofolate in preparing a medicine or health-care food for preventing neonatal congenital heart disease in peri-pregnancy and/or pregnant women has an effect of preventing congenital heart disease. The prophylactic dosage of the 5-methyltetrahydrofolate can be greater than 1 mg. Compared with synthetic folic acid, high-dose use has no teratogenic effect. Thus the 5-methyltetrahydrofolate can prevent birth defects in a high dose and can be used for preventing neonatal congenital heart disease.
ISOLATED MITOCHONDRIA WITH SMALLER SIZE AND LIPID MEMBRANE-BASED VESICLES ENCAPSULATING ISOLATED MITOCHONDRIA
According to the present invention, there is provided a composition comprising a population of mitochondria with a smaller size and a population of lipid membrane-based vesicles encapsulating mitochondria in a closed space and a method for producing the composition.
ISOLATED MITOCHONDRIA WITH SMALLER SIZE AND LIPID MEMBRANE-BASED VESICLES ENCAPSULATING ISOLATED MITOCHONDRIA
According to the present invention, there is provided a composition comprising a population of mitochondria with a smaller size and a population of lipid membrane-based vesicles encapsulating mitochondria in a closed space and a method for producing the composition.
NOVEL SUBSTITUTED CONDENSED RING COMPOUND
The present invention provides a novel compound having an excellent β-lactamase inhibitory effect. The present invention provides: a compound which has an excellent β-lactamase inhibitory effect, and is represented by formula (1a), (1b) or (11); or a pharmaceutically acceptable salt thereof. This compound provides a prophylactic or therapeutic agent effective for bacterial infections when used in combination with β-lactam-based drugs or used as a single agent. The present invention also provides a prophylactic or therapeutic agent effective for treating various diseases, by being used in combination with β-lactam-based drugs.
COMPOSITIONS AND METHODS INVOLVING AMINO ACIDS FOR THE TREATMENT OF FAT INFILTRATIONS IN MUSCLE
This disclosure provides methods of using compositions comprising amino acid entities to reduce fat infiltration in muscle, particularly under conditions of muscle dysfunction. The disclosure also provides methods for enhancing muscle function by reducing fat infiltration in the muscle comprising administering an effective amount of the compositions to a subject in need thereof.
COMPOSITIONS AND METHODS INVOLVING AMINO ACIDS FOR THE TREATMENT OF FAT INFILTRATIONS IN MUSCLE
This disclosure provides methods of using compositions comprising amino acid entities to reduce fat infiltration in muscle, particularly under conditions of muscle dysfunction. The disclosure also provides methods for enhancing muscle function by reducing fat infiltration in the muscle comprising administering an effective amount of the compositions to a subject in need thereof.
METHOD FOR INDUCING HEPATOCYTE PLASTICITY
The disclosure provides a method for producing hepatocytes or hepatic progenitor cells; a method for suppressing hepatocyte aging using a drug causing histone hyperacetylation; a hepatocyte anti-aging agent; a method for increasing hepatocyte plasticity; and a drug for increasing hepatocyte plasticity.